Medigus: Polyrizon Submits a Patent Application for Prevention of Pathogens such as Coronavirus and Allergens from Affecting Nasal Tissue
September 02 2021 - 7:31AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced that
Polyrizon Ltd., a privately held company which Medigus owns 35.86%
of its share capital, has submitted an additional patent
application to the United States Patent and Trademark Office for
its innovative technology.
The invention generally pertains to the field of
hydrogels that are capable to capture and contain biological
assaults intrusion through the upper airways and eye cavities.
Furthermore, the invention details a novel modality for a delivery
system for drugs through the nasal mucosa that could get more drug
into the body, and resides longer in the nasal cavity.
Recent pre-clinical data by Polyrizon, showed
that its product candidate has the potential to reduce the risk of
an infection with human coronavirus and may also prevent COVID-19
as well as Influenza Virus H1N1 and may potentially also treat
additional Cold viruses.
Polyrizon’s product candidate protects the nasal
cavity and the respiratory tract, prevents the virus from
colonizing in the upper respiratory, potentially decreases the
viral load and facilitates the immune system to control the virus
more effectively.
This pre-clinical data highlights the Capture
and Contain (C&C™) impact of Polyrizon’s product line that can
be extended against Coronavirus, Influenza and Cold viruses and a
variety of different respiratory viruses.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technologies company that is focused on innovative growth
partnerships, mainly in advanced medical solutions, digital
commerce, and electric vehicle markets. Medigus' affiliations in
the medical solutions arena consist of ownership in ScoutCam
(OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in
digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's
Brands and Eventer Technologies, Ltd. In the electric vehicle
market, Charging Robotics, Ltd. and Revolz are also part of the
Company’s portfolio of technology solution providers. Medigus is
traded on the Nasdaq Capital Market. To learn more about Medigus’
advanced technologies, please
visit http://www.medigus.com/investor-relations.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing conclusions from Polyrizon’s pre-clinical study,
the potential of Polyrizon’s product candidate on the viral load
and the immune system and the product candidate’s preventative
effect. These forward-looking statements represent Medigus’
expectations or beliefs concerning future events, and it is
possible that the results described in this press release will not
be achieved. By their nature, Forward-Looking Statements involve
known and unknown risks, uncertainties and other factors which may
cause future results of the Medigus’ activity to differ
significantly from the content and implications of such statements.
Other risk factors affecting Medigus and Polyrizon are
discussed in detail in the Medigus’ filings with the Securities and
Exchange Commission. Forward-Looking Statements are pertinent only
as of the date on which they are made, and Medigus undertakes no
obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or
otherwise. Neither Medigus nor its shareholders, officers and
employees, shall be liable for any action and the results of any
action taken by any person based on the information contained
herein, including without limitation the purchase or sale of
Medigus’ securities. Nothing in this press release should be deemed
to be medical or other advice of any kind.
Contact (for media only)
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024